Biopharmaceutical Boom Drives Cell Culture Market Growth

Biopharmaceutical Boom Drives Cell Culture Market Growth

Biopharmaceuticals have become a primary growth driver for not only pharmaceutical companies, but also upstream bioprocessing product suppliers. The production of vaccines, hormones, blood factors, thrombolytics, interferons, monoclonal antibodies and therapeutic enzymes requires cell culturing and the voluminous supply of culture media, sera, and reagents. The market for cell cultures is expected to grow rapidly alongside biopharmaceuticals and with significant evolution in culture technology. In Cell Culture: The Market for Media, Sera and Reagents, Kalorama Information examines the fast-growing cell culture market and its leading trends in terms of culture composition and culture application in biopharmaceutical production.

The rising demand for cell cultures is best captured through a brief timeline of biopharmaceutical product launches: only 13 biopharmaceuticals were approved in the United States and Europe between 1982 and 1990; 39 biopharmaceuticals were approved in those markets in the 1990s; 65 in the 2000s; 15 alone in 2010 between the United States and the European Union (EU); 12 in 2011; 16 in 2012; 13 in 2013; and 11 biopharmaceuticals in 2014. Biopharmaceutical production is increasing not only through the introduction of novel therapeutics, but also through the introduction of biosimilars or generic biopharmaceuticals able to be manufactured by several companies. The demand for culture materials including media, sera and reagents has consistently risen alongside biopharmaceutical production.

The increasing use of mammalian cell lines, including versatile and uniquely capable stem cells, in upstream bioprocessing has imposed specific demands on cell cultures: namely better-defined media. The rising stakes and production levels of companies active in biopharmaceuticals have dictated improved reproducibility or consistency in product; mitigation of the risk of contamination; and culture product more amenable to downstream processing or purification. These goals have been in part addressed by replacing sera, other animal-derived and poorly defined culture adjuncts with specialty media and well-defined reagents designed for mammalian cell culturing. The biopharmaceutical industry shift away from animal-derived culture products is expected to continue, particularly given the ascension of mammalian cell lines in biopharmaceutical production.

Cell Culture: The Market for Media, Sera and Reagents is the fifth edition of Kalorama Information’s market research report on world markets for cell culture media, sera, and reagents. The three market segments are sized, projected and profiled in the report in addition to the world market’s geographical segments and company market shares.

Kalorama Information also analyzes biopharmaceutical manufacturing with Biopharmaceutical and Vaccine Production Markets. The report segments spending for mammalian cell, microbial cell, monoclonal antibody, other recombinant protein, vaccine, and insulin manufacturing with forecasts to 2018.